NCT02579434View on ClinicalTrials.gov

Evaluation and Validation of Endogenous Markers for the Assessment of CYP3A Activity in Korean Healthy Subjects Using Metabolomics

PHASE1CompletedINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

May 31, 2015

Study Completion Date

April 30, 2016

Conditions
Healthy Volunteers
Interventions
DRUG

Midazolam I.V.

Midazolam I.V. 1mg/ml

Trial Locations (1)

Unknown

Jieon Lee, Seoul

All Listed Sponsors
lead

Seoul National University Hospital

OTHER

NCT02579434 - Evaluation and Validation of Endogenous Markers for the Assessment of CYP3A Activity in Korean Healthy Subjects Using Metabolomics | Biotech Hunter | Biotech Hunter